Clinical Trial Update: Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating neoadjuvant and adjuvant lenvatinib in hepatocellular carcinoma patients treated with percutaneous ablation. The study status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING